Common genetic polymorphisms and prognosis of sporadic cancers: Prostate cancer as a model

Future Oncology

Volumn 2, Issue 2, 2006, Pages 233-245

  Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen; Genetics; Growth factor; Microenvironment; Polymorphism; Prognosis; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; CYTOCHROME P450 17; CYTOCHROME P450 3A4; GROWTH FACTOR; SEX HORMONE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 2; UNCLASSIFIED DRUG; TUMOR PROTEIN;

CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL INTERACTION; DETOXIFICATION; DISEASE COURSE; DNA REPAIR; DRUG METABOLISM; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOMIC INSTABILITY; GROWTH REGULATION; HIGH RISK POPULATION; HORMONE SYNTHESIS; HUMAN; IMMUNE RESPONSE; MALE; MICROENVIRONMENT; MOLECULAR EPIDEMIOLOGY; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; XENOBIOTIC METABOLISM; GENETIC PREDISPOSITION; GENETICS; PROSTATE TUMOR;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 33646463651     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.2.233     Document Type: Review

References (134)

1. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87(2), 159-170, (1996).
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
3. Hunter K: Host genetics influence tumour metastasis. Nature Rev. Cancer 6(2), 141-146 (2006).
4. Gsur A, Feik E, Madersbacher S: Genetic polymorphisms and prostate cancer risk. World J. Urol 21, 414-423 (2004).
5. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer Incidence and mortality. Int. J. Cancer 85(1), 60-67 (2000).
6. Powell IJ, Banerjee M, Novallo, M et al.: Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than White men with locally advanced but not organ-confined disease. Urology 55(2), 246-251 (2000).
7. Powell. IJ. Dey J, Dudley A et al: Disease-free survival difference between African Americans and Whites after radical prostatectorny for local prostate cancer: a multivariable analysis. Urology 59 (6), 907-912 (2002).
8. Wu CP. Gu FL: The prostate in eunuchs. Prog. Clin. Biol. Res. 370, 249-255 (1991).
9. Thompson IM Jr, Kouril M, Klein EA et al: The prostate cancer prevention trial: current status and lessons learned. Urology 57(4 Suppl. 1), 230-234 (2001).
10. Huggim C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168(1), 9-12 (2002).
11. Breslow N, Chan CW Dhom G et al: Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer 20(5), 680-688 (1977).
12. Coughlin SS, Hall IJ: A review of genetic polymorphisms and prostate cancer risk. Ann. Epidemiol. 12(3), 182-196 (2002).
13. Thigpen AE, Silver RI, Guileyardo JM et al.: Tissue distribution and ontogeny of steroid 5 α-reductase isozyme expression. J. Clin. Invest. 92(2), 903-910 (1993).
14. Grino PB, Griffin JE, Wilson JD: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126(2), 1165-1172 (1990).
15. Hsing AW: Hormones and prostate cancer: what's next? Epidemiol. Rev. 23(1), 42-58 (2001).
16. Thomas LN, Douglas RC, Vessey JP et al.: 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J. Urol. 170(5), 2019-2025 (2003).
17. Shirakawa T, Okada H. Acharya B et al.: Messenger RNA levels and enzyme activities of 5 α-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 58 (1), 33-40 (2004).
18. Makridakis NM, Reichardt JK: Molecular epidemiology of hormone-metabollc loci in prostate cancer. Epidemiol. Rev. 23(1), 24-29 (2001).
19. Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl Acad Sci. USA 93(11), 5517-5521 (1996).
20. Irvine RA, Yu MC, Ross RK et al.: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55(9), 1937-1940 (1995).
21. Chamberiain NL, Driver ED, Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22(15), 3181-3186 (1994).
22. Lieberman AP, Harmison G, Strand AD et al.: Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet. 11(17), 1967-1976 (2002).
23. Giovannucci E, Stampfer MJ, Krithivas K et al.: The CAG repeat within the androgen receptor gene and Its relationship to prostate cancer. Proc. Natl Acad. Sci, USA 94(7), 3320-3323 (1997).
24. Stardord JL, Just JJ, Gibbs M et al.: Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57(6), 1194-1198 (1997).
25. Hsing AW, Gao YT, Wu G et al.: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60(18), 5111-5116 (2000).
26. Gao T, Marcelli M, McPhaul MJ: Transcriptional activation and transient expression of the human androgen receptor. J. Steroid Biochem. Mol. Biol. 59(1), 9-20 (1996).
27. Ding D, Xu L, Menon M et al.: Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Pratate 62 (2), 133-139 (2005).
28. Platz EA, Giovannucci E, Dahl DM et al.: The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol. Biomarkers. Prev. 7 (5), 379-384 (1998).
29. Edwards SM, Badzioch MD, Minter R et al.: Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer 84 (5), 458-465 (1999).
30. Strom SS, Gu Y, Zhang H et al.: Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4), 343-351 (2004).
31. Powell IJ, Land SJ, Dey J et al.: The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 103(3), 528-537 (2005).
32. Suzuki H, Akakura K, Komiya A et al: CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 51(3), 219-224 (2002).
33. Shimbo M, Suzuki H, Kamiya N et al.: CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur. Urol. 47(4), 557-563 (2005).
34. Relchardt JK, Makridakis N, Henderson BE et al: Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 55(18), 3973-3975 (1995).
35. Allen NE, Reichardt JK, Nguyen H et al: Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol. Biomarkers Prev. 12(6), 578-581 (2003).
36. Makridakis N, Ross RK, Pike MC et al: A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 57(6), 1020-1022 (1997).
37. Nam RK, Toi A, Vesprird D et al: V89L polymorphism of type-2, 5α reductase enzyme gene predicts prostate cancer presence and progression. Urology 57(1), 199-204 (2001).
38. Li Z, Habuchi T, Mitsumori K et al.: Association of V89L SR5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol. 169(6), 2378-2381 (2003).
39. Hsing AW, Chen C, Chokkalingam AP et al.: Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 10(10), 1077-1082 (2001).
40. Allen NE, Forrest MS, Key TJ: The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol. Biomarkers Prev. 10 (3), 185-189 (2001).
41. Lunn RM, Bell DA, Mohler JL et al: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRDSA2). Carcinogenesis 20(9), 1727-1731 (1999).
42. Ntais C, Polycarpou A, Ioannidis JP: SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12(7), 618-624 (2003).
43. Febbo PG, Kantoff PW, Platz EA et al.: The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res. 59(23), 5878-5881 (1999).
44. Salam MT, Ursin G, Skinner EC et al.: Associations between polymorphisms in the steroid 5α reductase type II (SRDSA2) gene and benign prostatic hyperplasia and prostate cancer. Urol. Oncol. 23(4), 246-253 (2005).
45. Jaffe JM, Malkowicz SB, Walker AH et al.: Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 60(6), 1626-1630 (2000).
46. Shibata A, Garcia MI, Cheng I et al.: Polymorphisms in the androgen receptor and type II 5α-reductase genes and prostate cancer prognosis. Prostate 52(4), 269-278 (2002)
47. Makridakis NM, Ross RK, Pike MC et al.: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354(9183), 975-978 (1999).
48. Mononen N, Ikonen T, Syrjakoski K et al.: A missense substitution A49T in the steroid 5α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br: J. Cancer 84 (10), 1344-1347 (2001).
49. Thompson IM, Goodman PJ, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3), 215-224 (2003).
50. Lunn RM, Bell DA, Mohler JL et al.: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20(9), 1727-1731 (1999).
51. Habuchi T, Liqing Z, Suzuki T et al.: Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60(20), 5710-5713 (2000).
52. Wadelius M, Andersson AO. Johansson JE et al: Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9(5), 635-639 (1999).
53. Gsur A, Bernhofer G, Hinteregger S et al.: A polymorphism in the CYP 17 gene is associated with prostate cancer risk. Int. J. Cancer 87(3), 434-437 (2000).
54. Ntais C, Polycarpou A, Ioannidis JP: Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12(2), 120-126 (2003).
55. Ellem SJ, Schmitt JF, Pedersen JS et al: Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab. 89(5), 2434-2441 (2004).
56. Voigt KD. Bartsch W: Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J. Steroid Biochem. 25(5B), 749-757 (1986).
57. Hiramatsu M, Maehara I, Ozaki M et al.: Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 31(2), 118-124 (1997).
58. Yeh S, Miyamoto H, Shima H et al.: From estrogen to androgen receptor: a new pathway for sex harmones in prostate. Proc. Natl Acad. Sci. USA 95(10), 5527-5532 (1998).
59. Farnsworth WE: Roles of estrogen and SHBG in prostate physiology. Prostate 28(1),17-23 (1996).
60. Haiman CA, Hankinson SE, Spiegelman D et al.: A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer 87(2), 204-210 (2000).
61. Somner J, McLellan S, Cheung J et al.: Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 89(1), 344-351 (2004).
62. Latil AG, Azzouzi R, Cancel GS et al.: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92 (5), 1130-1137 (2001).
63. Suzuki K, Nakazato H, Matsui H et al.: Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anti Cancer Res. 23(6D), 4941-4946 (2003).
64. Li L, Cicek MS, Casey G et al.: No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13(12), 2280-2281 (2004).
65. Guengerich FP: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).
66. Waxman DJ, Lapenson DP, Aoyama T et al.: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290(1), 160-166 (1991).
67. Keshava C, McCanlies EC, Weston A: CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am. J. Epidemiol. 160(9), 825-841 (2004).
68. Paris PL, Kupelian PA, Hall JM et al: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 8 (10), 901-905 (1999).
69. Spurdle AB, Goodwin B, Hodgson E et al.: The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12(5), 355-366 (2002).
70. Wandel. C, Witte JS, Hall JM et al.: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′ -.promoter region polymorphism. Clin. Pharmacol. Ther. 68(1), 82-91 (2000).
71. Westlind A, Lofberg L, Tindberg N et al.: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259(1), 201-205 (1999).
72. Rebbeck TR, Jaffe JM, Walker AH et al.: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90(16). 1225-1229 (1998).
73. Powell Ij, Zhou J, Sun Y et al.: CYP3A4 genetic variant and disease-free survival among White and Black men after radical prostatectomy. J. Urol, 172(5 Pt 1), 1848-1852 (2004).
74. Deshpande A, Sicinski P, Hinds PW: Cyclins and cdks In development and cancer: a perspective. Oncogene 24(17), 2909-2915 (2005).
75. Fu M, Wang C, Li Z et al.: Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145(12), 5439-5447 (2004).
76. Betticher DC, Thatcher N, Altermatt HJ et al.: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11 (5), 1005-1011 (1995).
77. Hosokawa Y, Gadd M, Smith AP et al.: Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett. 113 (1-2), 123-130 (1997).
78. Solomon DA, Wang Y, Fox SR et al.: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J. Biol. Chem. 278(32), 30339-30347 (2003).
79. Lu F, Gladden AB, Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 63, 7056-7061 (2003).
80. Wang L, Habuchi T, Takahashi T et al.: Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23(2), 257-264 (2002).
81. Wang L, Habuchl T, Mitsumori K et al.: Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int. J. Cancer 103(1), 116-120 (2003).
82. Le Marchand L, Seiffied A, Lum-Jones A et al.: Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 290(21), 2843-2848 (2003).
83. Kang S, Kim JW, Park NH et al.: Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol. Oncol. 97(2), 431-435 (2005).
84. Pakakasama S. Chen TT, Frawley W et al.: CCND1 polymorphism and age of onset of hepatoblastoma. Oncogene 23(27), 4789-4792 (2004).
85. Lewis RC, Bostick RM, Xie D et al.: Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res. 63(23), 8549-8553 (2003).
86. Qiuling S, Yuxin Z, Suinta Z et al: Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis 24(9), 1499-1503 (2003).
87. Izzo JG, Papadimitrakopoulou VA, Liu DD et al.: Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J. Natl Cancer Inst. 95(3), 198-205 (2003).
88. Zheng Y, Shen H, Sturgis EM et al.: Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 22(8),1195-1199 (2001).
89. Kibel AS, Suarez BK, Belani J et al.: CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 63(9), 2033-2036 (2003).
90. Aaltomaa S, Lipponen P, Eskelinen M et al.: Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 39(1), 8-15 (1999).
91. Lacombe L, Maillette A, Meyer F et al.: Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int. J. Cancer 95(3), 135-139 (2001).
92. Tsihlias J, Kapusta LR, DeBoer G et al.: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58(3), 542-548 (1998).
93. Yang RM, Naltoh J, Murphy M et al.: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159(3),941-945 (1998).
94. Morbidelli L, Donnini S, Ziche M: Role of nitric oxide in the modulation of angiogenesis. Curr: Pharm. Des. 9(7), 521-530 (2003).
95. Medeiros RM, Morais A, Vasconcelos A et al.: Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin. Cancer Res. 8(11), 3433-3437 (2002).
96. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92 (18), 1472-1489 (2000).
97. Larsson O, Girnita A, Girnita L: Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92 (12), 2097-2101 (2005).
98. Chan JM, Stampfer MJ, Giovannucci E et al.: Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279(5350), 563-566 (1998).
99. Chan JM, Stampfier MJ, Ma J et al.: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advancedstage prostate cancer. J. Natl Cancer Inst. 94(14), 1099-1106 (2002).
100. Shaneyfelt T, Husein R, Bubley G et al.: Hormonal predictors of prostate cancer: a meta-analysis. J. Clin. Oncol. 18(4), 847-853 (2000).
101. Stattin P Bylund A, Rinaldi S et al.: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl Cancer Inst. 92(23), 1910-1917 (2000).
102. Rotwein P, Pollock KM, Didier DK et al.: Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J. Biol. Chem. 261(11), 4828-4832 (1986)
103. Rosen CJ, Kurland ES, Vereault D et al.: Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density J. Clin. Endocrinol. Metab. 83(7), 2286-2290 (1998).
104. Jernstrom H, Chu W, Vesprini D et al.: Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1, implications for premenopausal breast cancer risk. Mol. Genet. Metab. 72(2), 144-154 (2001).
105. Tsuchiya N, Wang L, Horikawa Y et al.: CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int. J. Oncol. 26(1), 225-231 (2005).
106. Tsuchiya N, Wang L, Habuchi T et al.: Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J. Clin. Oncol. (2006) In press.
107. Baserga R: The insulin-like growth factor-I receptor as a target for cancer therapy. Exp. Opin. Ther. Targets 9(4), 753-768 (2005).
108. Watters JW, McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta. 1603(2), 99-111 (2003).
109. Townsend D, Tew K: Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3(3), 157-172 (2003).
110. Agundez JA: Cytochrome P450 gene Polymorphism and cancer. Curr. Drug Metab. 5(3), 211-224 (2004).
111. Ozawa S, Soyama A, Saeki M et al.: Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Dug Metab. Pharmacokinet 19(2), 83-95 (2004).
112. Weiss JM, Goode EL, Ladiges WC et al.: Polymorphic variation in hOGG1 and risk of cancer, a review of the functional and epidemiologic literature. Mol. Carcinog. 42(3), 127-141 (2005).
113. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11(12), 1513-1530 (2002).
114. Mohrenweiser HW: Genetic variation and exposure related risk estimation: will toxicology enter a new era? DNA repair and cancer as a paradigm. Toxicol. Pathol. 32(Suppl. 1), 136-145 (2004).
115. Fernet M, Hall J: Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst.) 3(8-9), 1237-1243 (2004).
116. Kumazawa T, Tsuchiya N, Wang L et al: Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int. J. Cancer 110(1), 140-144 (2004).
117. Devgan SA, Henderson BE, Yu MC et al.: Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 33(1), 9-12 (1997).
118. Margiotti K, Kim E, Pearce CL et al.: Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 53(1), 65-68 (2002).
119. Henner WD, Evans AJ, Hough KM, et al.: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 49(4), 263-266 (2001).
120. Rebbeck TR, Walker AH, Zeigler-Johnson C et al: Association of HPC2/ ELAC2 genotypes and prostate cancer. Am. J. Hum. Genet. 67(4), 1014-1019 (2000).
121. George DJ, Shepard TF, Ma J et al.: PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 10(4), 411-412 (2001).
122. Yokomizo A, Koga H, Kinukawa N et al.: Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility Prostate 62(1), 49-53 (2005).
123. Habuchi T, Suzuki T, Sasaki R et al.: Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 60(2), 305-308 (2000).
124. Lin CC, Wu HC, Tsai FJ or al.: Vascular endothelial growth factor gene - 460 C/T polymorphism is a biomarker for prostate cancer. Urology 62(2), 374-377 (2003).
125. Li Z, Habuchi T, Tsuchiya N et al.: Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon 10. Carcinogenesis 25(2), 237-240 (2004).
126. McCarron SL, Edwards S, Evans PR et al: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 62(12), 3369-3372 (2002).
127. Ye S: Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19(7), 623-629 (2000).
128. Rees J: Functional polymorphism in EGF gene and malignant melanoma. Lancet 360(9332), 570 (2002).
129. Gsur A, Haidinger G, Hinteregger S et al: Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int. J. Cancer 95(3), 152-155 (2001).
130. Ntais C, Polycarpou A, Ioannidis JP: Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 14(1), 176-181 (2005).
131. Wadelius M, Autrup JL, Stubbins MJ et al: Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 9(3), 333-340 (1999).
132. Goode EL, Ulrich CM, Potter JD: Polymorphisrns in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11-12), 1513-1530 (2002).
133. Angele S, Falconer A, Edwards SM et al: ATM polymorphisms as risk factors for prostate cancer development. Br. J. Cancer 91(4), 783-787 (2004).
134. Chang BL, Zheng SL, Isaacs; SD et al.: Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int. J Cancer 106(3), 375-378 (2003).